Cellectis (NASDAQ:CLLS) Stock Passes Below 50 Day Moving Average - Here's What Happened

Key Points

• Cellectis shares fell below their 50-day moving average, trading as low as $1.75 and closing at $1.83, compared with the $3.00 moving average.
• Analyst sentiment remains mixed but leans positive overall: the stock has a “Moderate Buy” consensus rating and a $7.00 average price target, despite one “sell” rating.
• The company exceeded quarterly EPS expectations, reporting a loss of $0.22 per share versus the projected $0.26 loss, but revenue of $6.90 million came in below the $11.05 million consensus estimate.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.00 and traded as low as $1.75. Cellectis shares last traded at $1.83, with a volume of 1,172,743 shares.

Wall Street Analysts Forecast Growth

CLLS has been the topic of several research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cellectis in a report on Friday, July 17th. Barclays began coverage on Cellectis in a research note on Thursday, May 28th. They issued an "overweight" rating and a $9.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $7.00.

Cellectis Price Performance

The stock has a market capitalization of $183.62 million, a P/E ratio of -2.82 and a beta of 2.92. The business has a fifty day simple moving average of $3.00 and a 200 day simple moving average of $3.34. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.04. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.The company had revenue of $6.90 million for the quarter, compared to analysts' expectations of $11.05 million.

Hedge Funds Weigh In On Cellectis

A hedge fund recently bought a new position in Cellectis stock. Lido Advisors LLC purchased a new stake in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 10,094 shares of the biotechnology company's stock, valued at approximately $32,000. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis' product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.